Anviron — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Anviron is an emerging oncology biotech leveraging a glycome-focused platform to develop inhibitors of glycosyltransferases, key enzymes in cancer signaling. Its pipeline is anchored by ANV221, which has demonstrated strong preclinical results in pancreatic ductal adenocarcinoma and drug-resistant HER2+ breast cancer models, leading to orphan drug designation for pancreatic cancer. The company, founded in 2020 (contradicting earlier data), has built a robust intellectual property portfolio with patents granted in the US, Europe, and Japan, and is supported by academic collaborations and a seasoned advisory board. Anviron is currently in the preclinical/IND-enabling stage, seeking investment to advance its lead programs toward clinical trials.

Oncology

Technology Platform

Small molecule inhibitors targeting glycosyltransferase enzymes (specifically DPAGT1) within the cancer glycobiome to disrupt protein glycosylation, a key driver of cancer proliferation and metastasis.

Opportunities

Anviron's novel glycobiome platform addresses high-unmet-need cancers like pancreatic and treatment-resistant HER2+ breast cancer, where current therapies often fail.

Orphan Drug Designation for ANV221 in pancreatic cancer provides potential for accelerated development and market exclusivity.

The ability to reverse drug resistance in HER2+ breast cancer creates a clear combination therapy pathway with established standards of care.

Risk Factors

The company is at a high-risk preclinical stage, where promising animal data may not translate to human efficacy or safety.

Targeting fundamental glycosylation pathways carries potential for on-target toxicity in healthy tissues.

As a private, pre-revenue company, it is dependent on raising significant capital to advance into clinical trials.

Competitive Landscape

The field of glycosylation-targeted cancer therapy is emerging but competitive, with several academic groups and biotechs (e.g., Palleon Pharmaceuticals, Enable Biosciences) exploring different angles of the glycobiology space. Anviron's specific focus on DPAGT1 inhibition differentiates it, but it will compete with numerous other novel modalities (e.g., ADCs, bispecifics, next-generation kinase inhibitors) also targeting resistant cancers.

More companies in Small Molecule Drugs →More companies in United States →